UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: September 30, 2019
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware
 
62-1559667
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
DVCR
OTCQX
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
Accelerated filer
 
¨
Non-accelerated filer
 
¨(do not check if a smaller reporting company)
Smaller reporting company
 
ý
 
 
 
Emerging growth company
 
¨
       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 
¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
6,675,161
(Outstanding shares of the issuer’s common stock as of October 28, 2019)
 




Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
September 30,
2019
 
December 31,
2018
 
(Unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
3,940

 
$
2,685

Receivables
62,036

 
66,257

Self-insurance receivables, current portion
1,672

 
4,475

Other receivables
1,849

 
1,191

Prepaid expenses and other current assets
4,278

 
4,659

Income tax refundable
778

 
1,115

Current assets of discontinued operations

 
155

Total current assets
74,553

 
80,537

PROPERTY AND EQUIPMENT, at cost
131,326

 
127,644

Less accumulated depreciation and amortization
(82,878
)
 
(76,801
)
Property and equipment, net
48,448

 
50,843

OTHER ASSETS:
 
 
 
Deferred income taxes, net

 
15,851

Deferred leasehold costs

 
206

Operating lease right-of-use assets
316,626

 

Acquired leasehold interest, net
5,869

 
6,307

Other noncurrent assets
3,644

 
3,244

Noncurrent assets of discontinued operations

 
2,256

Total other assets
326,139

 
27,864

 
$
449,140

 
$
159,244

The accompanying notes are an integral part of these interim consolidated financial statements.

2



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(continued)
 
 
September 30,
2019
 
December 31,
2018
 
(Unaudited)
 
 
CURRENT LIABILITIES:
 
 
 
Current portion of long-term debt and finance lease obligations, net
$
12,333

 
$
12,449

Trade accounts payable
14,401

 
15,659

Current liabilities of discontinued operations

 
86

Current portion of operating lease liabilities
22,986

 

Accrued expenses:
 
 
 
Payroll and employee benefits
16,969

 
19,471

Self-insurance reserves, current portion
12,235

 
13,158

Other current liabilities
11,468

 
9,522

Total current liabilities
90,392

 
70,345

NONCURRENT LIABILITIES:
 
 
 
Long-term debt and finance lease obligations, less current portion and deferred financing costs, net
63,167

 
60,984

Operating lease liabilities, less current portion
301,905

 

Self-insurance reserves, noncurrent portion
17,007

 
16,057

Litigation contingency, less current portion
9,000

 
6,400

Other noncurrent liabilities
1,497

 
6,656

Total noncurrent liabilities
392,576

 
90,097

COMMITMENTS AND CONTINGENCIES

 

SHAREHOLDERS’ DEFICIT:
 
 
 
Common stock, authorized 20,000 shares, $.01 par value, 6,907 and 6,751 shares issued, and 6,675 and 6,519 shares outstanding, respectively
69

 
68

Treasury stock at cost, 232 shares of common stock
(2,500
)
 
(2,500
)
Paid-in capital
23,883

 
23,413

Accumulated deficit
(55,832
)
 
(23,016
)
Accumulated other comprehensive income
552

 
837

Total shareholders’ deficit
(33,828
)

(1,198
)
 
$
449,140

 
$
159,244

The accompanying notes are an integral part of these interim consolidated financial statements.

3



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Three Months Ended September 30,
 
2019
 
2018
PATIENT REVENUES, net
$
118,630

 
$
119,035

EXPENSES:
 
 
 
Operating
95,591

 
95,768

Lease and rent expense
13,251

 
12,060

Professional liability
1,737

 
1,604

Litigation contingency expense (Note 7)

 
6,400

General and administrative
6,902

 
6,873

Depreciation and amortization
2,279

 
2,662

Total expenses
119,760

 
125,367

OPERATING LOSS
(1,130
)
 
(6,332
)
OTHER INCOME (EXPENSE):
 
 
 
Other income
25

 

Interest expense, net
(1,554
)
 
(1,382
)
Total other expense
(1,529
)
 
(1,382
)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(2,659
)
 
(7,714
)
BENEFIT FOR INCOME TAXES
741

 
252

LOSS FROM CONTINUING OPERATIONS
(1,918
)
 
(7,462
)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
 
 
 
Operating income (loss), net of tax provision of $459 and $45, respectively
(3,689
)
 
65

Gain on lease modification, net of tax
733

 

Income (loss) from discontinued operations
(2,956
)
 
65

NET LOSS
$
(4,874
)
 
$
(7,397
)
NET LOSS PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
(0.30
)
 
$
(1.17
)
Discontinued operations
(0.45
)
 
0.01

 
$
(0.75
)
 
$
(1.16
)
Per common share – diluted
 
 
 
Continuing operations
$
(0.30
)
 
$
(1.17
)
Discontinued operations
(0.45
)
 
0.01

 
$
(0.75
)
 
$
(1.16
)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$

 
$
0.055

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,470

 
6,400

Diluted
6,470

 
6,400

                              
The accompanying notes are an integral part of these interim consolidated financial statements.
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Three Months Ended September 30,
 
2019
 
2018
NET LOSS
$
(4,874
)
 
$
(7,397
)
OTHER COMPREHENSIVE INCOME (LOSS):
 
 
 
Change in fair value of cash flow hedge, net of tax
(37
)
 
46

Total other comprehensive income (loss)
(37
)
 
46

COMPREHENSIVE LOSS
$
(4,911
)
 
$
(7,351
)

The accompanying notes are an integral part of these interim consolidated financial statements.

4



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Nine Months Ended September 30,
 
2019
 
2018
PATIENT REVENUES, net
$
354,145

 
$
357,406

EXPENSES:

 
 
Operating
284,643

 
284,823

Lease and rent expense
39,480

 
36,105

Professional liability
5,182

 
4,898

Litigation contingency expense (Note 7)

3,100

 
6,400

General and administrative
21,267

 
23,046

Depreciation and amortization
6,812

 
7,686

Total expenses
360,484

 
362,958

OPERATING LOSS
(6,339
)
 
(5,552
)
OTHER INCOME (EXPENSE):
 
 
 
Gain on sale of investment in unconsolidated affiliate

 
308

Other income
207

 
113

Interest expense, net
(4,424
)
 
(4,147
)
Total other expense
(4,217
)
 
(3,726
)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(10,556
)
 
(9,278
)
BENEFIT (PROVISION) FOR INCOME TAXES

(15,544
)
 
903

LOSS FROM CONTINUING OPERATIONS
(26,100
)
 
(8,375
)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
 
 
 
Operating income (loss), net of tax provision of $570 and $222, respectively
(7,449
)
 
564

Gain on lease modification, net of tax
733

 

Income (loss) from discontinued operations
(6,716
)
 
564

NET LOSS
$
(32,816
)
 
$
(7,811
)
NET LOSS PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
(4.04
)
 
$
(1.32
)
Discontinued operations
(1.04
)
 
0.09

 
$
(5.08
)
 
$
(1.23
)
Per common share – diluted
 
 
 
Continuing operations
$
(4.04
)
 
$
(1.32
)
Discontinued operations
(1.04
)
 
0.09

 
$
(5.08
)
 
$
(1.23
)
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$

 
$
0.17

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,455

 
6,362

Diluted
6,455

 
6,362


The accompanying notes are an integral part of these interim consolidated financial statements.


5



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
Nine Months Ended September 30,
 
2019
 
2018
NET LOSS
$
(32,816
)
 
$
(7,811
)
OTHER COMPREHENSIVE INCOME (LOSS):
 
 
 
Change in fair value of cash flow hedge, net of tax
(285
)
 
501

Less: reclassification adjustment for amounts recognized in net income

 
(151
)
Total other comprehensive income (loss)
(285
)
 
350

COMPREHENSIVE LOSS
$
(33,101
)
 
$
(7,461
)

The accompanying notes are an integral part of these interim consolidated financial statements.


6



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)
(in thousands and unaudited)
 
Common Stock
 
Treasury Stock
 
Paid-in Capital
 
Accumulated Deficit
 
Accumulated
Other
Comprehensive Income (Loss)
 
Total
Shareholders' Equity(Deficit)
 
Shares Issued
 
Amount
 
Shares
 
Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BALANCE, DECEMBER 31, 2017
6,687

 
$
67

 
232

 
$
(2,500
)
 
$
22,720

 
$
(14,534
)
 
$
709

 
$
6,462

Net loss

 

 

 

 

 
(103
)
 

 
(103
)
Common stock dividends declared

 

 

 

 
13

 
(363
)
 

 
(350
)
Issuance/redemption of equity grants, net
86

 
1

 

 

 
(79
)
 

 

 
(78
)
Interest rate cash flow hedge

 

 

 

 

 

 
208

 
208

Stock-based compensation

 

 

 

 
236

 

 

 
236

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BALANCE, MARCH 31, 2018
6,773

 
68

 
232

 
(2,500
)
 
22,890

 
(15,000
)
 
917

 
6,375

Net loss

 

 

 

 

 
(311
)
 

 
(311
)
Common stock dividends declared

 

 

 

 
11

 
(362
)
 

 
(351
)
Issuance/redemption of equity grants, net
(5
)
 

 

 

 

 

 

 

Interest rate cash flow hedge

 

 

 

 

 

 
96

 
96

Stock-based compensation

 

 

 

 
348

 

 

 
348

BALANCE, JUNE 30, 2018
6,768

 
68

 
232

 
(2,500
)
 
23,249

 
(15,673
)
 
1,013

 
6,157

Net loss

 

 

 

 

 
(7,397
)
 

 
(7,397
)
Common stock dividends declared

 

 

 

 
9

 
(362
)
 

 
(353
)
Issuance/redemption of equity grants, net
(19
)
 

 

 

 
(140
)
 

 

 
(140
)
Interest rate cash flow hedge

 

 

 

 

 

 
46

 
46

Stock-based compensation

 

 

 

 
149

 

 

 
149

BALANCE, SEPTEMBER 30, 2018
6,749

 
68

 
232

 
(2,500
)
 
23,267

 
(23,432
)
 
1,059

 
(1,538
)
Net income

 

 

 

 

 
416

 

 
416

Issuance/redemption of equity grants, net
2

 

 

 

 

 

 

 

Interest rate cash flow hedge

 

 

 

 

 

 
(222
)
 
(222
)
Stock-based compensation

 

 

 

 
146

 

 

 
146

BALANCE, DECEMBER 31, 2018
6,751

 
68

 
232

 
(2,500
)
 
23,413

 
(23,016
)
 
837

 
(1,198
)
Net loss

 

 

 

 

 
(3,346
)
 

 
(3,346
)
Issuance/redemption of equity grants, net
163

 
1

 

 

 
41

 

 

 
42

Interest rate cash flow hedge

 

 

 

 

 

 
(63
)
 
(63
)
Stock-based compensation

 

 

 

 
140

 

 

 
140

BALANCE, MARCH 31, 2019
$
6,914

 
$
69

 
$
232

 
$
(2,500
)
 
$
23,594

 
$
(26,362
)
 
$
774

 
$
(4,425
)
The accompanying notes are an integral part of these interim consolidated financial statements.

7



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)
(in thousands and unaudited)
(continued)
 
Common Stock
 
Treasury Stock
 
Paid-in Capital
 
Accumulated Deficit
 
Accumulated
Other
Comprehensive Income (Loss)
 
Total
Shareholders' Equity(Deficit)
 
Shares Issued
 
Amount
 
Shares
 
Amount
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BALANCE, MARCH 31, 2019
6,914

 
$
69

 
232

 
$
(2,500
)
 
$
23,594

 
$
(26,362
)
 
$
774

 
$
(4,425
)
Net loss

 

 

 

 

 
(24,596
)
 

 
(24,596
)
Issuance/redemption of equity grants, net
(3
)
 

 

 

 

 

 

 

Interest rate cash flow hedge

 

 

 

 

 

 
(185
)
 
(185
)
Stock-based compensation

 

 

 

 
144

 

 

 
144

BALANCE, JUNE 30, 2019
6,911

 
$
69

 
232

 
$
(2,500
)
 
$
23,738

 
$
(50,958
)
 
$
589

 
$
(29,062
)
Net loss

 

 

 

 

 
(4,874
)
 

 
(4,874
)
Issuance/redemption of equity grants, net
(4
)
 

 

 

 

 

 

 

Interest rate cash flow hedge

 

 

 

 

 

 
(37
)
 
(37
)
Stock-based compensation

 

 

 

 
145

 

 

 
145

BALANCE, SEPTEMBER 30, 2019
6,907

 
$
69

 
232

 
$
(2,500
)
 
$
23,883

 
$
(55,832
)
 
$
552

 
$
(33,828
)

The accompanying notes are an integral part of these interim consolidated financial statements.


8



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 
 
Nine Months Ended September 30,
 
2019
 
2018
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net loss
$
(32,816
)
 
$
(7,811
)
Discontinued operations
(6,716
)
 
564

Loss from continuing operations
(26,100
)
 
(8,375
)
Adjustments to reconcile loss from continuing operations to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
6,812

 
7,686

Deferred income tax provision (benefit)
15,851

 
(829
)
Provision for self-insured professional liability, net of cash payments
4,682

 
2,224

Litigation contingency expense
3,100

 
6,400

Stock-based and deferred compensation
429

 
947

Gain on sale of unconsolidated affiliate

 
(308
)
Provision (benefit) for leases in excess of cash payments
3,768

 
(1,363
)
Other
643

 
251

Changes in assets and liabilities affecting operating activities:
 
 
 
Receivables, net
7,024

 
(2,134
)
Prepaid expenses and other assets
(4,071
)
 
(2,379
)
Trade accounts payable and accrued expenses
(3,451
)
 
2,391

Net cash provided by continuing operations
8,687

 
4,511

Discontinued operations
(5,130
)
 
1,153

Net cash provided by operating activities
3,557

 
5,664

NET CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(3,745
)
 
(4,689
)
Proceeds from sale of unconsolidated affiliate

 
308

Net cash used in continuing operations
(3,745
)
 
(4,381
)
Discontinued operations
6

 
(1,275
)
Net cash used in investing activities
(3,739
)
 
(5,656
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repayment of debt and finance lease obligations
(6,867
)
 
(15,330
)
Proceeds from issuance of debt
8,477

 
17,203

Financing costs
(215
)
 
(137
)
Issuance and redemption of employee equity awards, net
42

 
(219
)
Payment of common stock dividends

 
(1,053
)
Payment for preferred stock restructuring

 
(508
)
Net cash provided by (used in) continuing operations
1,437

 
(44
)
Discontinued operations

 

Net cash provided by (used in) financing activities
$
1,437

 
$
(44
)
The accompanying notes are an integral part of these interim consolidated financial statements.

9



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 
Nine Months Ended September 30,
 
2019
 
2018
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
$
1,255

 
$
(36
)
CASH AND CASH EQUIVALENTS, beginning of period
2,685

 
3,524

CASH AND CASH EQUIVALENTS, end of period
$
3,940

 
$
3,488

SUPPLEMENTAL INFORMATION:
 
 
 
Cash payments of interest
$
4,100

 
$
4,511

Cash payments of income taxes
$
241

 
$
474

SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:

 
 
 
Acquisition of equipment through finance leases
$
234

 
$
203

Acquisition of operating leases though adoption of ASC 842
$
389,403

 
$

Lease modification
$
(48,877
)
 
$

The accompanying notes are an integral part of these interim consolidated financial statements.

10



DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2019 AND 2018
(Dollars and shares in thousands, except per share data)
(Unaudited)

1.
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of September 30, 2019, the Company’s continuing operations consist of 62 nursing centers with 7,329 licensed nursing beds. The Company owns 15 and leases 47 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted and residential living beds. On August 30, 2019, the Company terminated operations of ten centers in Kentucky, which included 885 licensed nursing beds.

2.
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements for the three and nine month periods ended September 30, 2019 and 2018, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2019, and the results of operations, and changes in shareholders' deficit for the three and nine month periods ended September 30, 2019 and 2018, and cash flows for the nine month period ended September 30, 2019 and 2018. The Company’s balance sheet information at December 31, 2018, was derived from its audited consolidated financial statements as of December 31, 2018.
Effective January 1, 2019, we adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), as discussed in Notes 3 and 6 to the interim consolidated financial statements. Effective January 1, 2018, we adopted the requirements of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standards.
The results of operations for the periods ended September 30, 2019 and 2018 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Discontinued Operations
On December 1, 2018, the Company sold three Kentucky properties for a purchase price of $18.7 million, which are collectively referred to as the "Kentucky Properties." On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. These ten centers are collectively referred to as the "Kentucky Centers." The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." As a result of the Kentucky Exit, the Company no longer operates any skilled nursing centers in the State of Kentucky. The Company's exit from the state represents a strategic shift that has (or will have) a major effect on the Company's financial position, results of operations and cash flows. In accordance with ASC 205, the Company's discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these operations. Refer to Note 12, "Discontinued Operations" for more information.

3.
RECENT ACCOUNTING GUIDANCE

Recent Accounting Standards Adopted by the Company
In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income

11



statement. For short-term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make (and the Company chose to utilize) an accounting policy election by asset class not to recognize ROU assets and lease liabilities, which would generally result in lease expense for these short term leases being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company elected to use the optional expedient to reflect adoption in the period of adoption (January 1, 2019) rather than the earliest period presented. The Company also elected the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The adoption of the new standard resulted in the recording of net lease assets and lease liabilities of $384,187 and $389,403, respectively, as of January 1, 2019. The standard did not materially impact our consolidated net earnings and had no impact on cash flows. See Note 6, "Leases" for a discussion regarding leases under the new standard.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures. In October 2018, the FASB issued ASU No. 2018-16, Derivatives and Hedging (Topic 805): Inclusion of the Secured Overnight Financing Rate ("SOFR") Overnight Index Swap ("OIS") Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. The ASU amends ASC 815 to add the OIS rate based on the SOFR as a fifth US benchmark interest rate. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures.
In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvement to Nonemployee Share-Based Payment Accounting, which modifies the accounting for share-based payment awards issued to nonemployees to largely align it with the accounting for share-based payment awards issued to employees. The standard is effective for fiscal years beginning after December 15, 2018. The Company adopted the requirements of this standard effective January 1, 2019. The adoption did not have a material impact on our consolidated financial statements and related disclosures.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. The new guidance is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's services. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments.

12



This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements of fair value measurements under Topic 820. The standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.

4. REVENUE RECOGNITION
On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's services. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.
The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.
Disaggregation of Revenue and Accounts Receivable
The following table summarizes revenue from contracts with customers by payor source from continuing operations for the periods presented (dollar amounts in thousands):

13



 
Three Months Ended September 30,
 
2019
 
2018
Medicaid
$
57,191

48.2
%
 
$
55,910

47.0
%
Medicare
19,274

16.2
%
 
20,318

17.1
%
Managed Care
11,794

9.9
%
 
11,248

9.4
%
Private Pay and other
30,371

25.7
%
 
31,559

26.5
%
Total
$
118,630

100.0
%
 
$
119,035

100.0
%
 
Nine Months Ended September 30,
 
2019
 
2018
Medicaid
$
164,815

46.5
%
 
$
159,706

44.7
%
Medicare
59,211

16.7
%
 
64,713

18.1
%
Managed Care
37,911

10.7
%
 
36,748

10.3
%
Private Pay and other
92,208

26.1
%
 
96,239

26.9
%
Total
$
354,145

100.0
%
 
$
357,406

100.0
%


14



Accounts receivable from continuing operations as of September 30, 2019 and December 31, 2018 are summarized in the following table:
 
September 30
 
December 31,
 
2019
 
2018
Medicaid
$
25,366

 
$
27,532

Medicare
10,686

 
15,706

Managed Care
8,376

 
8,126

Private Pay and other
17,608

 
14,893

Total accounts receivable
$
62,036

 
$
66,257



5.
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $59,645 as of September 30, 2019, consisting of $50,245 on the term loan facility with an interest rate of 6.00% and $9,400 on the acquisition loan facility with an interest rate of 6.75%. The Amended Mortgage Loan is secured by fifteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Revolving Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000.
Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
Effective December 1, 2018, the Company entered into the Sixth Amendment ("Sixth Revolver Amendment") to amend the Amended Revolver. The Sixth Amendment decreased the Amended Revolver capacity from $52,250 to $42,250. The Company also applied $4,947 of net proceeds from the sale of the Kentucky Properties to the outstanding borrowings under the Amended Revolver.
Effective December 1, 2018, the Company executed a Fourth Amendment (the "Fourth Term Amendment") to amend the Amended Mortgage Loan. The Company applied $11,100 and $2,100 of net proceeds from the sale of the Kentucky Properties to the Term Loan and Acquisition Loan, respectively. Additionally, we amended the Acquisition Loan availability to include a reserve of

15



$2,100, and therefore, our borrowing capacity is $10,400. For further discussion of the sale of the Kentucky Properties, refer to Note 12, "Discontinued Operations."
On August 30, 2019, the Company completed a transaction to exit Kentucky and no longer operates any skilled nursing centers in the state. The Company entered into a consent under the Amended Revolver to remove the Kentucky Properties as borrowers. Refer to Note 12, "Discontinued Operations" for more information.
The Company is participating in the Texas Quality Incentive Payment Program ("QIPP"). Effective May 13, 2019, the Company entered into a Fifth Amendment (the “Fifth Term Amendment”) to amend the Amended Mortgage Loan to release the operators of three of the QIPP centers in Texas from the Amended Mortgage Loan and a Seventh Amendment (the “Seventh Revolver Amendment”) to amend the Amended Revolver to remove the operators of all four of the QIPP centers in Texas from the Amended Revolver and to permanently reduce the amount available under the Amended Revolver by $2,000. At the same time, the operators of these four facilities entered into a separate revolving loan (the "affiliated revolver") with the same syndicate of banks to provide for the temporary working capital requirements of the four QIPP centers. The affiliated revolver, which is guaranteed by the Company, has an initial capacity of $5,000, which amount is reduced by $1,000 on each of January 1, 2020, April 1, 2020 and July 1, 2020. The affiliated revolver has the same maturity date as the Amended Revolver and the Amended Mortgage Loan of February 26, 2021. The affiliated revolver is cross-defaulted with the Amended Revolver and the Amended Mortgage Loan. For further discussion of the QIPP centers in Texas, refer to Note 11, "Business Development and Other Significant Transactions." As of September 30, 2019, the Company had $2,000 borrowings outstanding under the affiliated revolver. The interest rate related to the affiliated revolver was 6.00% as of September 30, 2019.
As of September 30, 2019, the Company had $14,000 borrowings outstanding under the Amended Revolver compared to $15,000 outstanding as of December 31, 2018. The interest rate related to the Amended Revolver was 6.00% as of September 30, 2019. The outstanding borrowings on the revolver were used primarily for temporary working capital requirements. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has four letters of credit with a total value of $12,017 outstanding as of September 30, 2019. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $32,284 the balance available for borrowing under the Amended Revolver and affiliated revolver was $4,267 at September 30, 2019.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at September 30, 2019.
Interest Rate Swap Transaction
Pursuant to the Company's debt agreements, the Company has an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company's interest rate swap is designated as a cash flow hedge, and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $27,015 as of September 30, 2019. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at September 30, 2019, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net liability of $77 at September 30, 2019. The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s interim consolidated balance sheet. The change in the interest rate swap liability is included in accumulated other comprehensive income at September 30, 2019 is $60 net of the income tax provision of $17. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.

6.     LEASES

The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.

16




Leases
 
 
Classification
 
September 30, 2019
Assets
 
 
 
 
   Operating lease assets
 
Operating lease assets
 
$
316,626

   Finance lease assets
 
Property and equipment, net (a)
 
972

Total leased assets
 
 
 
$
317,598

 
 
 
 
 
Liabilities
 
 
 
 
Current
 
 
 
 
   Operating
 
Current portion of operating lease liabilities
 
$
22,986

   Finance
 
Current portion of long-term debt and finance lease obligations, net

 
273

Noncurrent
 
 
 
 
   Operating
 
Operating lease liabilities
 
301,905

   Finance
 
Long-term debt and finance lease obligations, less current portion and deferred financing costs, net

 
508

Total lease liabilities
 
 
 
$
325,672

 
 
 
 
 
(a) Finance lease assets are recorded net of accumulated amortization of $1,456 as of September 30, 2019.

Lease Cost
 
 
 
 
Three Months Ended
 
Nine Months Ended
 
 
Classification
 
September 30, 2019
 
September 30, 2019
Operating lease cost (a)
 
Lease and rent expense
 
$
13,251

 
$
39,480

Finance lease cost:
 
 
 
 
 
 
   Amortization of finance lease assets
 
Depreciation and amortization
 
54

 
196

   Interest on finance lease liabilities
 
Interest expense, net
 
11

 
37

Short term lease cost
 
Operating expense
 
169

 
472

Net lease cost
 
 
 
$
13,485

 
$
40,185

 
 
 
 
 
 
 
(a) Includes variable lease costs, which are immaterial
 
 

Maturity of Lease Liabilities
As of September 30, 2019
 
 
Operating Leases (a)
 
Finance Leases (a)
 
Total
 
 
 
 
 
 
 
2019
 
$
50,592

 
$
313

 
$
50,905

2020
 
51,533

 
243

 
51,776

2021
 
52,553

 
206

 
52,759

2022
 
53,593

 
65

 
53,658

2023
 
53,897

 
27

 
53,924

After 2023
 
214,168

 

 
214,168

Total lease payments
 
$
476,336

 
$
854

 
$
477,190

Less: Interest
 
(151,445
)
 
(73
)
 
(151,518
)
Present value of lease liabilities
 
$
324,891

 
$
781

 
$
325,672

 
 
 
 
 
 
 
(a)  Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.


17



The Company's future minimum lease commitments for continuing operations as of December 31, 2018, under Accounting Standards Codification Topic 840, predecessor to Topic 842, are as follows:
As of December 31, 2018
 
 
Operating Leases (a)
 
Finance Leases (a)
 
Total
 
 
 
 
 
 
 
2018
 
$
48,701

 
$
454

 
$
49,155

2019
 
49,595

 
174

 
49,769

2020
 
50,570

 
173

 
50,743

2021
 
51,587

 
127

 
51,714

2022
 
52,624

 

 
52,624

After 2022
 
245,225

 

 
245,225

Total lease payments
 
$
498,302

 
$
928

 
$
499,230

 
 
 
 
 
 
 
(a)  Operating and Finance lease payments exclude option to extend lease terms that are not reasonably certain of being exercised.

The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a collateralized basis over a similar term.

Lease Term and Discount Rate
 
 
September 30, 2019
 
 
 
Weighted-average remaining lease term (years)
 
 
   Operating leases
 
9.04
   Finance leases
 
2.02
Weighted-average discount rate
 
 
   Operating leases
 
8.9%
   Finance leases
 
5.5%

Other Information
 
 
Nine Months Ended
 
 
September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities
 
 
   Operating cash flows for operating leases
 
$
42,816

   Operating cash flows for finance leases
 
$
37

   Financing cash flows for finance leases
 
$
373

Acquisition of operating leases though adoption of ASC 842
 
$
389,403

Lease modification
 
$
(48,877
)

7.    COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits

18



per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $26,680 and $27,201 as of September 30, 2019 and December 31, 2018, respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of September 30, 2019, the Company is engaged in 91 professional liability lawsuits. Thirty-one lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs were $5,398 and $5,088 for the nine months ended September 30, 2019 and 2018, respectively.
The Company follows the accounting guidance in ASC Topic 954 that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Self-insurance receivables" on the Consolidated Balance Sheet. As of September 30, 2019 and December 31, 2018 there are estimated insurance recovery receivables of $2,305 and $5,475, respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ also obtained testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.

19



In June, 2019, the Company and the DOJ reached an agreement in principle on the financial terms of a settlement regarding this investigation. The Company has agreed to the settlement in principle in order to avoid the uncertainty and expense of litigation.
Based on the agreement in principle and in anticipation of the execution of final agreements and payment of a settlement amount of $9,500 (the “Settlement Amount”) the Company recorded an additional loss contingency expense in the amount of $3,100 in the second quarter of 2019, to increase its previously estimated and recorded liability related to this investigation, of which based on the payment terms of the settlement in principle, $500 has been recorded as a current liability. The Company expects to remit the Settlement Amount to the government over a period of five (5) years, once the settlement has been fully documented and executed, and further expects the settlement to require a contingent payment in the event the Company sells any of its owned facilities during the five year payment period and a payment of attorneys' fees to relator's counsel.
The agreement in principle is subject to negotiation, completion and execution of appropriate implementing agreements, including a settlement agreement and a corporate integrity agreement, which are expected to be finalized prior to the end of 2019, and the final approval of the respective parties. There can be no assurance that the Company will enter into a final settlement agreement with the DOJ. The Company denies any wrong doing and is prepared to vigorously defend its actions if a settlement is not reached.

Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. From the period from July 1, 2008 through September 30, 2019, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $806 and $618 at September 30, 2019 and December 31, 2018, respectively. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,538 and $1,258 as of September 30, 2019 and December 31, 2018, respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of September 30, 2019, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,756 at September 30, 2019. The differences between actual settlements and reserves are included in expense in the period finalized.

8.
STOCK-BASED COMPENSATION

Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.


20



Equity Grants and Valuations
During the nine months ended September 30, 2019 and 2018, the Compensation Committee of the Board of Directors approved grants totaling approximately 151 and 90 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest one-third on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares.
In computing the fair value estimates for options and stock-only stock appreciation rights ("SOSARs") using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Upon vesting of equity awards, all restrictions are removed. Our policy is to account for forfeitures of share-based compensation awards as they occur.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2018
122

 
$
7.29

Granted

 

Exercised
(2
)
 
2.37

Expired or cancelled
(22
)
 
8.33

Outstanding, September 30, 2019
98

 
$
7.17

 
 
 
 
Exercisable, September 30, 2019
89

 
$
7.05


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2018
120

 
$
8.77

Granted
151

 
3.93

Vested
(58
)
 
8.91

Cancelled
(7
)
 
5.97

Outstanding, September 30, 2019
206

 
$
5.28


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2018
43

 
$
9.26

Granted
36

 
3.93

Vested
(30
)
 
9.76

Outstanding, September 30, 2019
49

 
$
5.05



21



The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2019:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.21
 
$
8.83

 
45

 
$

 
35

 
$

$5.45 to $5.86
 
$
5.76

 
54

 
$

 
54

 
$

 
 
 
 
99

 
 
 
89

 
 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $429 and $947 in the nine month periods ended September 30, 2019 and 2018, respectively.
9. INCOME TAXES
The Company recorded an income tax provision of $15,544 during the nine months ended September 30, 2019 and a benefit of $903 during the nine months ended September 30, 2018.
When assessing the recoverability of the Company’s recorded deferred tax assets, the accounting guidance, ASC 740, Income Taxes, requires that all available positive and negative evidence be considered in evaluating the likelihood that the Company will be able to realize the benefit of its deferred tax assets in the future, which is highly judgmental. Such evidence includes, but may not be limited to, scheduled reversals of deferred tax assets and liabilities, projected future taxable income, tax-planning strategies, and the results of recent operations.
When assessing all available evidence, the Company recognized that governmental and regulatory changes have put downward revenue pressure on the long-term care industry as a piece of negative evidence in its analysis. In 2019 and 2018 combined, the Company recognized a total expense of $9.5 million related to the CID settlement in principle. Additionally, in 2017 it recorded an additional $5.5 million of income tax expense related to the revaluation of deferred tax assets in accordance with the Tax Cuts and Jobs Act. Because of these items and other financial results, the Company entered a cumulative loss for the 36 preceding months ended June 30, 2019 and performed a thorough assessment of the available positive and negative evidence in order to ascertain whether it is more likely than not that in future periods the Company will generate sufficient pre-tax income to utilize all of its federal deferred tax assets and its net operating loss and other carryforwards and credits.
The Company also identified several pieces of positive evidence that were considered and weighed in the analysis performed regarding the valuation of deferred tax assets. The evidence included the termination of operations for 10 nursing facilities in Kentucky completed in the third quarter of 2019, the related corporate and regional restructuring and other cost saving initiatives already in process. The evidence also included consideration of participation in revenue incentive programs that are expected to generate additional revenue, the long-term expiration dates of a majority of the net operating losses and credits, and the Company’s history of not having carryforwards or credits expire unutilized.
In performing the analysis, the Company contemplated utilization of the recorded deferred tax assets under multiple scenarios. After consideration of these factors, the Company determined that a full valuation allowance of $20.0 million was necessary as of June 30, 2019. As of September 30, 2019, the Company has a valuation allowance in the amount of $21.1 million.  The Company will continue to periodically assess the realizability of its future deferred tax assets.
The Company is not currently under examination by any major income tax jurisdiction. During 2019, the statutes of limitations will lapse on the Company's 2015 Federal tax year and certain 2014 and 2015 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the nine months ended September 30, 2019 and 2018.



22




10.
EARNINGS PER COMMON SHARE
Information with respect to basic and diluted net loss per common share is presented below in thousands, except per share:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Net loss
 
 
 
 
 
 
 
Loss from continuing operations
$
(1,918
)
 
$
(7,462
)
 
$
(26,100
)
 
$
(8,375
)
Income (loss) from discontinued operations, net of income taxes
(2,956
)
 
65

 
(6,716
)
 
564

Net loss
$
(4,874
)
 
$
(7,397
)
 
$
(32,816
)
 
$
(7,811
)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Net loss per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Loss from continuing operations
$
(0.30
)
 
$
(1.17
)
 
$
(4.04
)
 
$
(1.32
)
Income (loss) from discontinued operations
(0.45
)
 
0.01

 
(1.04
)
 
0.09

Net loss per common share – basic
$
(0.75
)
 
$
(1.16
)
 
$
(5.08
)
 
$
(1.23
)
Per common share – diluted
 
 
 
 
 
 
 
Loss from continuing operations
$
(0.30
)
 
$
(1.17
)
 
$
(4.04
)
 
$
(1.32
)
Income (loss) from discontinued operations
(0.45
)
 
0.01

 
(1.04
)
 
0.09

Net loss per common share – diluted
$
(0.75
)
 
$
(1.16
)
 
$
(5.08
)
 
$
(1.23
)
Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,470

 
6,400

 
6,455

 
6,362

Diluted
6,470

 
6,400

 
6,455

 
6,362

The effects of 98 and 226 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the nine months ended September 30, 2019 and 2018, respectively, because these securities would have been anti-dilutive.

11.
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2018 New Master Lease Agreement
On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by the Lessor and operated by Diversicare. The old Master Lease with the Lessor provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operated 11 centers owned by the Lessor under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and the Lessor consolidated the leases for all 34 centers under one New Master Lease. The Lease has an initial term of twelve years with two optional 10-year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.
On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. The agreement effectively amended the Master Lease Agreement with Omega Healthcare Investors to remove the ten Kentucky facilities, reduce the annual rent expense, and release the Company from any further obligations arising under the Master Lease Agreement with respect to the Kentucky facilities. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15% beginning on October 1, 2019.


23



Quality Incentive Payment Program
The Company recently expanded its participation in QIPP as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures. The Company previously had one of its Texas skilled nursing centers participating in the QIPP. During April 2019, the Company enrolled an additional eleven of its Texas skilled nursing centers in the program, such that twelve of the Company’s centers participate in the QIPP effective September 1, 2019. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the provider license from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district.

12.
DISCONTINUED OPERATIONS
Kentucky Disposition
On October 30, 2018 the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation, LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, LLC, Diversicare of Clinton, LLC and Diversicare of Glasgow, LLC (the "Kentucky Properties"). On December 1, 2018, the Company completed the sale of the Kentucky Properties with the Buyers for a purchase price of $18,700. This transaction did not meet the accounting criteria to be reported as a discontinued operation. The carrying value of these centers' assets was $13,331, resulting in a gain of $4,825, with remaining proceeds for miscellaneous closing costs. The proceeds were used to relieve debt, which is required under the terms of the Company's Amended Mortgage Loan and Amended Revolver. Refer to Note 5, "Long-term Debt and Interest Rate Swap" for more information on this transaction.
On May 22, 2019, the Company announced that it entered into an agreement with Omega to amend its master lease to terminate operations of ten nursing facilities, totaling approximately 885 skilled nursing beds, located in Kentucky and to concurrently transfer operations to an operator selected by Omega. These ten centers are collectively referred to as the "Kentucky Centers." The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." On August 30, 2019, the Company completed the transaction and no longer operates any skilled nursing centers in the State of Kentucky. The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." The Company's exit from the state represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results. In accordance with ASC 205, the Company's discontinued financial position, results of operations and cash flows have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these operations.
The transaction resulted in a gain on the modification of the Omega lease, which is presented within Discontinued Operations on the Consolidated Statements of Operations. The pretax gain on the transaction was $733.
The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.
The discontinued assets and liabilities of the disposed skilled nursing centers have been reclassified and are segregated in the interim consolidated balance sheets as assets and liabilities of discontinued operations.The Company did not transfer the accounts receivable or liabilities, inclusive of the reserves for professional liability and workers' compensation, to the new operator. The Company expects to collect the balance of the accounts receivable and pay the remaining liabilities in the ordinary course of business through its future operating cash flows.


24



A summary of the Kentucky Exit discontinued operations follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
PATIENT REVENUES, net
$
11,812

 
$
22,396

 
$
46,019

 
$
66,392

EXPENSES:
 
 
 
 
 
 
 
Operating
9,229

 
18,031

 
36,947

 
52,694

Lease and rent expense
1,792

 
1,704

 
7,169

 
5,097

Professional liability
2,468

 
1,329

 
5,401

 
3,992

General and administrative
259

 
664

 
985

 
1,925

Depreciation and amortization
1,287

 
302

 
2,250

 
1,006

Operating income (loss)
(3,223
)
 
366

 
(6,733
)
 
1,678

Other income
728

 
36

 
736

 
2

Interest expense, net
(2
)
 
(284
)
 
(149
)
 
(849
)
Income (loss) from discontinued operations before taxes
(2,497
)
 
118

 
(6,146
)
 
831

Income tax (expense) benefit
(459
)
 
(45
)
 
(570
)
 
(233
)
Income (loss) from discontinued operations, net of tax
$
(2,956
)
 
$
73

 
$
(6,716
)
 
$
598


A summary of other discontinued operations follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Loss from discontinued operations before taxes

 
(8
)
 

 
(45
)
Income tax benefit

 

 

 
11

Loss from discontinued operations, net of tax
$

 
$
(8
)
 
$

 
$
(34
)


A summary of cash inflows and outflows related to the the Kentucky Exit discontinued operations follows:
 
Nine Months Ended September 30,
 
2019
 
2018
Net cash provided by (used in) operating activities

(5,130
)
 
1,153

Net cash provided by (used in) investing activities

6

 
(1,275
)



25



ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas. The Company's operating results also include the results of discontinued operations in the state of Kentucky that have been reclassified on the face of the financial statements to reflect the discontinued status of these operations.
As of September 30, 2019, the Company’s continuing operations consist of 62 nursing centers with 7,329 licensed nursing beds. The Company owns 15 and leases 47 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted living and residential beds.
Key Performance Metrics
Skilled Mix. Skilled mix represents the number of days our Medicare or Managed Care patients are receiving services at the skilled nursing facilities divided by the total number of days (less days from assisted living patients).
Average rate per day. Average rate per day is the revenue by payor source for a period at the skilled nursing facility divided by actual patient days for the revenue source for a given period.
Average daily skilled nursing census. Average daily skilled nursing census is the average number of patients who are receiving skilled nursing care.
Strategic Operating Initiatives
We identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives include: improving our facilities' quality metrics, improving skilled mix in our nursing centers, improving our average Medicare rate, implementing and maintaining Electronic Medical Records (“EMR”) to improve Medicaid capture, and completing strategic acquisitions and divestitures. We have experienced success in these initiatives and expect to continue to build on these improvements.
Improving skilled mix and average Medicare rate:
One of our key performance indicators is skilled mix. Our strategic operating initiatives of improving our skilled mix and our average Medicare rate required investing in nursing and clinical care to treat more acute patients along with nursing center-based marketing representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract payor sources for patients covered by Medicare and Managed Care. The Company's skilled mix for the three months ended September 30, 2019 and 2018 was 13.3% and 14.0%, respectively. The Company's skilled mix for the nine months ended September 30, 2019 and 2018 was 14.2% and 15.1%, respectively.
Utilizing Electronic Medical Records to improve Medicaid acuity capture:
As another part of our strategic operating initiatives, all of our nursing centers utilize EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. By using EMR, we have increased our average Medicaid rate despite rate cuts in certain acuity based states by accurate and timely capture of care delivery.
Completing strategic transactions and other business developments:
Our strategic operating initiatives include a focus on completing strategic acquisitions and divestitures. We continue to pursue and investigate opportunities to acquire or lease new centers, focusing primarily on opportunities within our existing geographic areas of operation. As part of our strategic efforts, we routinely perform thorough analyses on our existing centers in order to determine whether continuing operations within certain markets or regions is in line with the short-term and long-term strategy of the business.
On December 1, 2018, the Company sold three Kentucky properties for a purchase price of $18.7 million, which are collectively referred to as the "Kentucky Properties." On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. These ten centers are collectively referred to as the "Kentucky Centers." The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." As a result of the Kentucky Exit, the Company no longer operates any skilled nursing centers in the State of Kentucky. The Kentucky Exit represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results. In accordance with ASC 205, the Company's discontinued operating results have been reclassified on the face of the financial statements and footnotes to reflect the discontinued status of these operations. Refer to Note 12, "Discontinued Operations" to the interim consolidated financial statements.

26



The Company recently expanded its participation in The Texas Quality Incentive Program ("QIPP") as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures. The Company previously had one of its Texas skilled nursing centers participating in the QIPP. During April 2019, the Company enrolled an additional eleven of its Texas skilled nursing centers in the program, such that twelve of the Company’s centers participate in the QIPP effective September 1, 2019. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the related provider licenses from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district.
On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor")